GET DAILY SIGNALSClorox (CLX) Analysts Point to $114 Target, Suggesting +14% Upside Potential
Key Takeaways
- The $114 central target is the arithmetic mean of the two verified analyst price targets that remain above the current share price — RBC Capital at $110 and Rothschild & Co Redburn at $117 — because the broader consensus average sits below the latest price.
- The latest verified price for CLX is about $99.96, meaning a move to $114 would require a roughly 14% advance.
- For context, the overall mean of all tracked analyst targets is about $97.75 (S&P Global Market Intelligence, 18 analysts), below the current price, while individual targets span a wide $74 to $117.
- Supporting factors include a faster-than-expected GOJO (Purell) integration, recovering market share, and a relatively undemanding valuation.
- The biggest risks are roughly $240 million in input-cost inflation, a value-seeking consumer, an elevated dividend payout ratio, higher debt, and an ongoing CEO transition.
- For more detail on the company, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
Analyst Price Targets and Consensus View
The Clorox Company (NYSE: CLX), the Oakland, California-based consumer staples manufacturer behind Clorox bleach, Glad, Kingsford, Brita, Burt's Bees, Hidden Valley, Pine-Sol, and Purell, is a stock, not an exchange-traded fund. Its analyst coverage is unusually divided: the Street's consensus rating is a "Hold" that tilts cautious, and the average 12-month target of roughly $97.75 sits slightly below the latest share price.
Because a consensus below the current price provides no meaningful upside benchmark, the $114 central target is calculated as the average of only the two verifiable targets that remain above the current price: RBC Capital at $110 (Hold) and Rothschild & Co Redburn at $117 (Hold). The full range across all valid targets is wide — from Goldman Sachs at $74 (Sell) to Rothschild & Co Redburn at $117 — with most estimates clustered between the high $70s and low $100s. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent revisions skew lower. Morgan Stanley lifted its target to $94 while maintaining Hold, UBS moved to $96, J.P. Morgan trimmed to $86 (Sell), Bank of America cut to $96, Wells Fargo's Chris Carey raised to $90, and TD Cowen lowered to $80. Jefferies downgraded the stock to Hold from Buy in July 2026. Analysts broadly cite cost inflation and soft consumer demand for the cautious stance, while the higher targets reflect confidence in margin recovery and the GOJO integration.
Current Market Position and Path Toward the Target
At roughly $99.96, CLX would need to advance about 14% to reach $114 — a substantial move for a defensive, low-beta (0.58) household-products name. The stock trades within a 52-week range of $79.12 to $128.90 and has underperformed the broader market over the past year.
The path toward $114 would likely require sustained organic-sales improvement, visible margin recovery, and successful execution of the GOJO (Purell) acquisition. Clorox guided fiscal 2027 adjusted EPS to $5.70–$6.00 and net sales growth of 13–14%, largely reflecting the GOJO deal. With shares near 15 times forward earnings, multiple expansion plus earnings growth would both need to contribute. The company reported better-than-expected fiscal first-quarter results, with improving organic sales and market share, though it now expects EPS near the lower end of guidance because of higher input costs.
What Could Support a Move Toward the Target
- GOJO integration ahead of plan: Management now expects the Purell acquisition to be EPS-accretive in year one, versus an originally neutral outlook, with roughly $50 million in cost synergies becoming visible.
- Market-share recovery: Home Care has posted eight straight quarters of share gains, while Hidden Valley and Glad have returned to positive momentum.
- Cost-savings execution: The company reported one of its highest quarterly cost-savings results, with targeted pricing and revenue-growth-management actions planned for the back half of the fiscal year.
- Valuation and income: A forward P/E around 15 and a dividend yield near 5% offer a potentially attractive entry point if earnings stabilize.
What Could Prevent the Target From Being Reached
- Input-cost inflation: Clorox now anticipates about $240 million in fiscal 2027 input-cost inflation, roughly 2.5 times its historical norm, pressuring gross margin.
- Consumer pressure: A value-seeking shopper and intense competition, including private-label products, could limit pricing power and volume growth.
- Balance-sheet and dividend strain: Total debt roughly doubled to about $5.1 billion, and the payout ratio is elevated near 103%, which is unsustainable without earnings growth.
- Leadership transition: Chair and CEO Linda Rendle is stepping down, adding execution uncertainty during a pivotal integration period.
Technical Levels and Market Structure
CLX has spent recent months below its 200-day moving average near $100, and the stock remains well below its 52-week high of $128.90. The $100 level now serves as both a psychological marker and an area of prior consolidation. A sustained push above $100–$105 would be an early technical signal of momentum toward the $114 area, while the $79–$88 zone represents major support near the 52-week low.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month horizon, though the two targets behind the $114 figure were set at different times and embed different assumptions about margin recovery. Investors should watch quarterly earnings and guidance updates, input-cost and commodity trends (particularly resin and oil), the pace of GOJO synergies, any pricing actions, market-share data, and the CEO succession. Changes in analyst targets — which have been trending lower — will also be a key signal for the stock forecast.
Using Tickeron AI Tools in Research
In my own analysis workflow, Tickeron’s AI Daily Buy/Sell Signals provide a useful layer of AI-driven monitoring for names like CLX. The platform scans thousands of securities in real time and flags Buy, Sell, or Hold signals based on technical behavior and market shifts, which can help surface timely context around sentiment changes without replacing fundamental work.
Final Assessment
The $114 central target is not a consensus forecast; it is the average of the two analyst targets still above the current price, and it sits well above the Street's overall mean of roughly $97.75. Reaching it would require a substantial roughly 14% advance driven by margin recovery, successful GOJO integration, and sustained market-share gains. Offsetting this are significant cost inflation, a cautious consumer, balance-sheet strain, and a leadership transition. The wide $74–$117 target range underscores genuine disagreement about Clorox's earnings trajectory. Investors should monitor earnings, cost trends, synergies, and analyst revisions rather than treat $114 as a foregone conclusion.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CLX's Stochastic Oscillator is remaining in overbought zone for 7 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
CLX broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on CLX as a result. In 41 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 42%.
The Moving Average Convergence Divergence (MACD) for CLX just turned positive on October 05, 2026. Looking at past instances where CLX's MACD turned positive, the stock continued to rise in 22 of 47 cases over the following month. The odds of a continued upward trend are 47%.
CLX moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CLX crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
Following a +0.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLX advanced for three days, in 179 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 75 of 193 cases where CLX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 39%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 10 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLX's P/B Ratio (134.314) is slightly higher than the industry average of (21.731). P/E Ratio (20.739) is within average values for comparable stocks, (16.288). Projected Growth (PEG Ratio) (1.019) is also within normal values, averaging (1.518). Dividend Yield (0.050) settles around the average of (0.032) among similar stocks. P/S Ratio (1.542) is also within normal values, averaging (1.902).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of detergent and cleaning products
Industry HouseholdPersonalCare
Advertisement